22:58 , Jul 10, 2019 |  BC Extra  |  Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Tesevatinib: Phase II started

Kadmon began an open-label, U.S. Phase II trial to evaluate 300 mg oral tesevatinib once daily in up to 40 patients with recurrent glioblastoma. Kadmon has rights to tesevatinib under a 2010 deal with Symphony...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Company News

Gyros, Protein Technologies deal

Gyros and Protein merged to form Gyros Protein Technologies AB (Tuscon, Ariz.). The newco will provide tools for the discovery, development and manufacturing of biotherapeutics. Gyros’ products include its Gyrolab xP workstation. Protein’s products include...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

Tesevatinib: Phase II started

Kadmon began an open-label, U.S. Phase II trial to evaluate 300 mg oral tesevatinib once daily in up to 40 NSCLC patients with EGFR activating mutations previously treated with a TKI and whose disease has...
08:00 , Nov 23, 2015 |  BioCentury  |  Finance

Community chorus

Newly formed Boston Pharmaceuticals is armed with $600 million to occupy one section of the drug development continuum: IND through Phase II proof of concept. To do so, the company plans to amass 20-25 assets...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

Tesevatinib: Interim Phase Ib/IIa data

Interim data from 10 patients with HER2-positive metastatic breast cancer with disease progression with or without metastases in the Phase Ib portion of an open-label, U.S. Phase Ib/IIa trial showed that once-daily 150, 250 and...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Echo Therapeutics diagnostic news

Echo engaged PricewaterhouseCoopers LLP to explore financial and strategic alternatives, which could include sale of assets, merger, capital transaction or petition for bankruptcy. In September, Echo suspended its operations to conserve liquidity and capital resources...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

SD-101: Phase I/II started

Dynavax began the open-label, dose-escalation, U.S. Phase I/II LYM-01 trial to evaluate 5 weekly intratumoral injections of 1, 2, 4 and 8 mg SD-101 given after 2 days of localized low-dose radiation in up to...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Echo Therapeutics diagnostic news

Echo said that it suspended its operations to conserve liquidity and capital resources because the company believes that it has insufficient resources to fund its needs beyond Sept. 30. The suspension follows a strategic review...